Skip to main content
Mijn bibliotheek
Ga naar:
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
BSL Shop
Inloggen

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

» Andere revante producten voor THIM studenten en medewerkers.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research

25-02-2025 | Review

Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis

Auteurs: Zhenzhi Wang, Yukun Chen, Xinyu Li, Li Lin, Bozhu Chen, Min Chen, Hui Zheng

Gepubliceerd in: Quality of Life Research

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Objectives

The impact of placebo response on health outcomes in various diseases, including IBS, is significant. To better understand the effect of different placebo administration methods on the observed outcomes in IBS studies, this meta-analysis aims to explore research findings on the degree of improvement.

Methods

The meta-analysis included 45 randomized, double-blind, placebo-controlled clinical trials involving 5174 patients with confirmed IBS (excluding those with significant comorbidities). The trials were designed to compare the efficacy of different placebo interventions. The primary outcome was the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS), and secondary outcomes included the Irritable Bowel Syndrome Quality of Life Instrument (IBS-QoL) and the IBS Symptom Visual Analog Scale (VAS). An arm-based Bayesian network meta-analysis was performed to examine the relative effectiveness of the placebo interventions on the outcomes.

Results

The analysis revealed that sham moxibustion exhibited the most significant efficacy in reducing IBS-SSS (MD -260.00, 95% CrIs: -288.00 to -232.00). Additionally, sham FMT resulted in significant improvements in IBS-QOL scores (MD 9.23, 95% CrIs − 3.69 to 22.30). Meanwhile, placebo tablet interventions were found to be the most effective in reducing VAS scores (MD 4.71, 95% CrIs, -1.14 to 11.10). Overall, this synthesis provides detailed insights into the effectiveness of placebos in addressing different outcome measures.

Conclusions

Sham moxibustion appears to provide subjective benefits for patients’ IBS symptoms. However, the evidence for its efficacy is less robust compared to other interventions, as assessed by GRADE. Understanding the placebo effect in IBS management is crucial for clinical practice and drug development, particularly in placebo comparisons.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Qu, Y., Park, S. H., & Dallas, D. C. (2023). Evaluating the potential of Casein Glycomacropeptide in Adult Irritable Bowel Syndrome Management: A pilot study. Nutrients, 15, 4174.PubMedPubMedCentralCrossRef
2.
3.
Chey, W. D., Kurlander, J., & Eswaran, S. (2015). Irritable bowel syndrome: A clinical review. Journal of the American Medical Association, 313, 949–958.PubMedCrossRef
4.
Spiller, R. (2021). Impact of Diet on symptoms of the irritable bowel syndrome. Nutrients 13.
5.
Weber, H. C. (2022). Irritable bowel syndrome and diet. Current Opinion in Endocrinology, Diabetes, and Obesity, 29, 200–206.PubMedCrossRef
6.
Ng, Q. X., et al. (2023). What has longitudinal ‘Omics’ studies taught us about Irritable Bowel Syndrome? A systematic review. Metabolites, 13, 484.PubMedPubMedCentralCrossRef
7.
Shah, E., & Pimentel, M. (2014). Placebo effect in clinical trial design for irritable bowel syndrome. Journal of Neurogastroenterology and Motility, 20, 163–170.PubMedPubMedCentralCrossRef
8.
Patel, S. M., et al. (2005). The placebo effect in irritable bowel syndrome trials: A meta-analysis. Neurogastroenterology and Motility, 17, 332–340.PubMedCrossRef
9.
Pitz, M., Cheang, M., & Bernstein, C. N. (2005). Defining the predictors of the placebo response in irritable bowel syndrome. Clinical Gastroenterology and Hepatology, 3, 237–247.PubMedCrossRef
10.
Enck, P., & Klosterhalfen, S. (2020). Placebo responses and Placebo effects in Functional Gastrointestinal disorders. Frontiers in Psychiatry, 11, 797.PubMedPubMedCentralCrossRef
11.
Klein, K. B. (1988). Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology, 95, 232–241.PubMedCrossRef
12.
Pergialiotis, V., et al. (2020). An arm-based network meta-analysis on treatments for vulvar lichen sclerosus and a call for development of core outcome sets. American Journal of Obstetrics and Gynecology, 222, 542–550e6.PubMedCrossRef
13.
Kokkotou, E., et al. (2010). Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterology and Motility, 22, 285–e81.PubMedCrossRef
14.
Centeno-Gándara, L. A. (2021). Improving the physician-patient relationship utilizing psychodynamic psychology: A primer for health professionals. Health Psychol Behav Med, 9, 338–349.PubMedPubMedCentralCrossRef
15.
Munkombwe, W. M., Petersson, K., & Elgán, C. (2020). Nurses’ experiences of providing nonpharmacological pain management in palliative care: A qualitative study. Journal of Clinical Nursing, 29, 1643–1652.PubMedCrossRef
16.
17.
Yoon, J. Y., et al. (2018). Probiotics Ameliorate Stool consistency in patients with chronic constipation: A Randomized, Double-Blind, placebo-controlled study. Digestive Diseases and Sciences, 63, 2754–2764.PubMedCrossRef
18.
Mezzasalma, V. (2016). A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. Biomed Res Int 4740907 (2016).
19.
Sudha, M. R., Jayanthi, N., Aasin, M., Dhanashri, R. D., & Anirudh, T. (2018). Efficacy of Bacillus coagulans unique IS2 in treatment of irritable bowel syndrome in children: A double blind, randomised placebo controlled study. Benef Microbes, 9, 563–572.PubMedCrossRef
20.
Begtrup, L. M., de Muckadell, O. B., Kjeldsen, J., Christensen, R. D., & Jarbol, D. E. (2013). Long-term treatment with probiotics in primary care patients with irritable bowel syndrome–a randomised, double-blind, placebo controlled trial. Scandinavian Journal of Gastroenterology, 48, 1127–1135.PubMedCrossRef
21.
Storsrud, S., Ponten, I., & Simren, M. A. (2015). Pilot study of the Effect of Aloe barbadensis Mill. Extract (AVH200(R)) in patients with irritable bowel syndrome: A Randomized, Double-Blind, placebo-controlled study. J Gastrointestin Liver Dis, 24, 275–280.PubMedCrossRef
22.
Coban, S., et al. (2012). Clinical trial: Transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study. Digestion, 86, 86–93.PubMedCrossRef
23.
Sharbafchi, M. R., et al. (2020). Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome. J Res Med Sci, 25, 115.PubMedPubMedCentralCrossRef
24.
Chen, M., et al. (2018). Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 48, 160–168.CrossRef
25.
Shin, S. Y., et al. (2020). The Effect of Phloroglucinol in patients with diarrhea-predominant irritable bowel syndrome: A Randomized, Double-blind, placebo-controlled trial. Journal of Neurogastroenterology and Motility, 26, 117–127.PubMedPubMedCentralCrossRef
26.
Heydari, P., et al. (2023). A double-blind randomized clinical trial of Dracocephalum Kotschyi Boiss. In the patients with diarrhea-predominant irritable bowel syndrome. Res Pharm Sci, 18, 89–99.PubMedCrossRef
27.
Jalili, M., Vahedi, H., Poustchi, H., & Hekmatdoost, A. (2019). Effects of vitamin D supplementation in patients with irritable bowel syndrome: A Randomized, Double-Blind, placebo-controlled clinical trial. Int J Prev Med, 10, 16.PubMedPubMedCentralCrossRef
28.
Khalilian, A., Ahmadimoghaddam, D., Saki, S., Mohammadi, Y., & Mehrpooya, M. (2021). A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. Biopsychosoc Med, 15, 3.PubMedPubMedCentralCrossRef
29.
Alt, F., Chong, P. W., Teng, E., & Uebelhack, R. (2017). Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the symptomatic improvement of irritable bowel syndrome: A Double-Blinded, randomised, placebo-controlled clinical trial. Phytotherapy Research: Ptr, 31, 1056–1062.PubMedCrossRef
30.
Arrouk, R., Herdes, R. E., Karpinski, A. C., & Hyman, P. E. (2018). Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome. Pediatric Health Med Ther, 9, 129–133.PubMedPubMedCentralCrossRef
31.
Williams, C. E., Williams, E. A., & Corfe, B. M. (2022). Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: Results of a randomised controlled trial. European Journal of Nutrition, 61, 299–308.PubMedCrossRef
32.
Shavakhi, A., et al. (2014). The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res, 3, 140.PubMedPubMedCentralCrossRef
33.
Mazzawi, T., Hausken, T., Refsnes, P. F., Hatlebakk, J. G., & Lied, G. A. (2022). The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study. Microorganisms 10.
34.
Urgesi, R., Casale, C., Pistelli, R., Rapaccini, G. L., & de Vitis, I. (2014). A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox(R)) in patients with irritable bowel syndrome. European Review for Medical and Pharmacological Sciences, 18, 1344–1353.PubMed
35.
Martoni, C. J., Srivastava, S., & Leyer, G. J. (2020). Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients 12.
36.
Rao, S., et al. (2020). Randomised clinical trial: Linaclotide vs placebo-a study of bi-directional gut and brain axis. Alimentary Pharmacology & Therapeutics, 51, 1332–1341.CrossRef
37.
Lewis, E. D. (2020). Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients 12.
38.
Francavilla, R., et al. (2019). Clinical and microbiological effect of a Multispecies Probiotic supplementation in Celiac patients with persistent IBS-type symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. Journal of Clinical Gastroenterology, 53, e117–e125.PubMedPubMedCentralCrossRef
39.
Zhou, Q., et al. (2019). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut, 68, 996–1002.PubMedCrossRef
40.
El-Salhy, M., Hatlebakk, J. G., Gilja, O. H., Brathen, K. A., & Hausken, T. (2020). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut, 69, 859–867.PubMedCrossRef
41.
Skrzydlo-Radomanska, B. (2020). The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients 12.
42.
Preston, K., et al. (2018). Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: A double-blind, randomised, placebo-controlled study. Benef Microbes, 9, 697–706.PubMedCrossRef
43.
Sun, Y. Y., et al. (2018). The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Scientific Reports, 8, 2964.PubMedPubMedCentralCrossRef
44.
Saito, Y. A., et al. (2019). Randomised clinical trial: Pregabalin vs placebo for irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 49, 389–397.CrossRef
45.
Chakraborty, D. S., Hazra, A., Sil, A., & Pain, S. (2019). Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Family Med Prim Care, 8, 3173–3178.PubMedPubMedCentralCrossRef
46.
El, A. D., Hassan, S., El, A. H., Yousef, M., & Hodeib, H. (2018). Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association, 24, 109–114.CrossRef
47.
Singh, P., et al. (2022). Effect of antibiotic pretreatment on bacterial engraftment after fecal microbiota transplant (FMT) in IBS-D. Gut Microbes, 14, 2020067.PubMedPubMedCentralCrossRef
48.
Lowe, C., Aiken, A., Day, A. G., Depew, W., & Vanner, S. J. (2017). Sham acupuncture is as efficacious as true acupuncture for the treatment of IBS: A randomized placebo controlled trial. Neurogastroenterology Motil, 29, e13040.CrossRef
49.
Ford, A. C., et al. (2023). Amitriptyline at Low-Dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 402, 1773–1785.PubMedCrossRef
50.
Tack, J., et al. (2017). The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut, 66, 1403–1413.PubMedCrossRef
51.
Barraza-Ortiz, D. A., et al. (2021). Combination of a probiotic and an Antispasmodic increases Quality of Life and reduces symptoms in patients with irritable bowel syndrome: A pilot study. Digestive Diseases, 39, 294–300.PubMedCrossRef
52.
Ki Cha, B., et al. (2012). The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Gastroenterology, 46, 220–227.PubMedCrossRef
53.
Aroniadis, O. C., et al. (2019). Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: A double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol, 4, 675–685.PubMedCrossRef
54.
55.
Majeed, M., Nagabhushanam, K., Arumugam, S., Majeed, S., & Ali, F. (2018). Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: A randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr Res 62.
56.
Williams, E. A., et al. (2009). Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics, 29, 97–103.CrossRef
57.
Lu, W. Z., Gwee, K. A., Moochhalla, S., & Ho, K. (2005). Y. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: A double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics, 22, 927–934.CrossRef
58.
Wang, Z., et al. (2022). Mild moxibustion for irritable bowel syndrome with Diarrhea (IBS-D): A randomized controlled trial. Journal of Ethnopharmacology, 289, 115064.PubMedCrossRef
59.
Song, G. H., Leng, P. H., Gwee, K. A., Moochhala, S. M., & Ho, K. (2005). Y. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: A randomised, double blind, placebo controlled study. Gut, 54, 1402–1407.PubMedPubMedCentralCrossRef
60.
Camacho-Diaz, B. H. (2023). The Effects of Agave Fructans in a Functional Food Consumed by Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 15.
61.
Gaudino, M. (2019). Prevalence and impact of treatment crossover in cardiac surgery randomized trials: A Meta-epidemiologic study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 8.
62.
Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. Plos Medicine, 7, e1000251.PubMedPubMedCentralCrossRef
63.
Krol, F. J., et al. (2020). Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials? European Neuropsychopharmacology, 32, 1–11.PubMedCrossRef
64.
Viera, A. J., & Bangdiwala, S. I. (2007). Eliminating bias in randomized controlled trials: Importance of allocation concealment and masking. Family Medicine, 39, 132–137.PubMed
65.
Hammami, M. M. (2016). Drug*placebo interaction effect may bias clinical trials interpretation: Hybrid balanced placebo and randomized placebo-controlled design. BMC Medical Research Methodology 16.
66.
Sliva, J., Pantzartzi, C. N., & Votava, M. (2019). Inosine pranobex: A key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther, 36, 1878–1905.PubMedPubMedCentralCrossRef
67.
Winkelbeiner, S., Leucht, S., Kane, J. M., & Homan, P. (2019). Evaluation of differences in Individual Treatment Response in Schizophrenia Spectrum disorders. JAMA Psychiatry, 76, 1063–1073.PubMedPubMedCentralCrossRef
68.
Li, R., et al. (2022). Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis. Front Med (Lausanne), 9, 1018713.PubMedCrossRef
Metagegevens
Titel
Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis
Auteurs
Zhenzhi Wang
Yukun Chen
Xinyu Li
Li Lin
Bozhu Chen
Min Chen
Hui Zheng
Publicatiedatum
25-02-2025
Uitgeverij
Springer New York
Gepubliceerd in
Quality of Life Research
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-025-03927-w